HomeBUSINESS
BUSINESS

Mitsubishi Tanabe Seeks to Call Off Cell Therapy Deal with South Korea’s KLS
(Dec.21.2017)

Mitsubishi Tanabe Pharma said on December 20 that it plans to discontinue the development in Japan of Invossa, a cell therapy for the treatment of knee osteoarthritis licensed from South Korea’s Kolon Life Science, for an unspecified reason ...
(LOG IN FOR FULL STORY)